Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Statins may have negative effects on some cardiac patients, says study

Although statins are widely used to prevent heart attacks, strokes, and other cardiovascular disorders, new research shows that the class of drugs may actually have negative effects on some cardiac patients. A new study presented at CHEST 2009, the 75th annual international scientific assembly of the American College of Chest Physicians (ACCP), found that statins have beneficial effects on patients with systolic heart failure (SHF), but those with diastolic heart failure (DHF) experienced the opposite effect, including increased dyspnea, fatigue, and decreased exercise tolerance.

4 Nov 2009

John Simpson named the 2009 Distinguished Alumnus for his invention

Back in the 1970s, while watching an angioplasty to widen clogged coronary arteries, John Simpson, Ph.D., M.D., thought there had to be an easier way to perform the procedure.

31 Oct 2009

Celsius RMT ThermoCool catheter of Stereotaxis receives CE Mark for distribution in the European market

Stereotaxis received notice that the Celsius® RMT ThermoCool® catheter has received CE Mark for distribution in the European market. The product is the fifth advanced ablation catheter resulting from the on-going co-development agreement between Stereotaxis and Biosense Webster to design and distribute magnetically enabled catheters for use in the Niobe Magnetic Navigation System (MNS).

30 Oct 2009

CCS updates the Canadian guidelines for the management and treatment of dyslipidemia

The management of dyslipidemia continues to evolve and despite improvements in recurrent cardiovascular events and a decrease in cardiac mortality, cardiovascular disease (CVD) still represents the major burden of disease in this country.

29 Oct 2009

Treatment of angina patients with ivabradine reduces risk of cardiovascular death

Dramatic reductions in hospitalization for heart attacks and in the need for revascularization surgery were achieved in angina patients treated with the selective heart rate reduction medication ivabradine on top of current standard treatment, according to results of a major clinical study presented today at the 2009 Canadian Cardiovascular Congress in Edmonton.

29 Oct 2009

NovaDel and Mist Acquisition enter into licensing agreement to manufacture and commercialize NitroMist

NovaDel Pharma Inc., has entered into a licensing agreement with privately-held Mist Acquisition, LLC to manufacture and commercialize the NitroMist® lingual spray version of nitroglycerine, a widely-prescribed and leading short-acting nitrate for the treatment of angina pectoris.

28 Oct 2009

Cappella introduces new Sideguard stent; expands commercial operations

Cappella, Inc. (Cappella), a medical device company developing dynamic solutions for the treatment of coronary bifurcation disease, announces that an additional diameter has been added to the Sideguard® platform.

26 Oct 2009

Exercise and lifestyle changes are key to improve heart health

Exercise is a wonderful way of boosting heart health, but it's proving to be a tough sell in Ontario South Asian communities, Dr. Milan Gupta told the Canadian Cardiovascular Congress 2009, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.

26 Oct 2009

Obese patients less likely to achieve cholesterol and blood pressure control

Obese patients taking medications to lower their blood pressure and cholesterol levels are less likely to reach recommended targets for these cardiovascular disease risk factors than their normal weight counterparts, according to new research presented at the 2009 Canadian Cardiovascular Congress hosted by the Canadian Cardiovascular Society and the Heart and Stroke Foundation of Canada.

26 Oct 2009

CHMP grants positive opinion to extend the use of Angiox to patients undergoing PCI

The Medicines Company announced today that the Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion applicable to all Member States of the European Union/European Economic Area that will extend the use of Angiox (bivalirudin) to include patients with heart attacks (so-called ST segment elevation myocardial infarction (STEMI)) undergoing emergency heart procedures called primary percutaneous coronary intervention (PCI).

24 Oct 2009

Learn to recognise stroke symptoms and take action: World Stroke Organization

The theme of this year's World Stroke Day on 29th October is "What can I do?". As the World Stroke Organization says, everyone can do something: learn to recognise symptoms and take action, learn to recognise the risk factors and take action.

24 Oct 2009

King Pharmaceuticals receives FDA complete response letter for CorVue NDA

King Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for CorVue™ (binodenoson) for injection.

21 Oct 2009

Three deaths in Detroit Marathon highlight the importance of greater public awareness about SDC

The tragic deaths of three runners in Sunday's Detroit Marathon underscore how frequently and indiscriminately sudden cardiac arrest strikes Americans, the Sudden Cardiac Arrest Association said today.

20 Oct 2009

Boehringer Ingelheim Pharmaceuticals receives NDA approval from FDA for its Micardis Tablets 80 mg

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for its angiotensin II receptor blocker (ARB) Micardis® (telmisartan) Tablets 80 mg for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take angiotensin-converting enzyme (ACE) inhibitors.(1) MICARDIS is the most studied ARB in this high-risk patient population and has been commercially available to treat hypertension (high blood pressure) since its approval in 1998.

19 Oct 2009

Coronary angiography does not affect kidney functioning in CKD patients, reveals study

A screening test that measures whether a patient's heart is healthy enough for a kidney transplant is not as dangerous as once thought, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN).

19 Oct 2009

Research to investigate and improve patient adherence to prescription drug therapies

CVS Caremark is sponsoring research to investigate patient adherence to prescription drug therapies and identify ways to increase adherence. Working with researchers from Harvard and Brigham and Women's Hospital, the company expects knowledge gained from the research will help health professionals better understand patient behavior and lead to developing programs that health care providers and pharmacies can use to improve medication adherence and ultimately help improve patient care and medical outcomes by avoiding costly hospital treatment.

15 Oct 2009

Abbott announces financial results for the third quarter ended Sept. 30, 2009

Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2009.

14 Oct 2009

Medtronic commences study of the Zotarolimus-Eluting Peripheral Stent System for treating erectile dysfunction

Medtronic, Inc., announced today the initiation of a feasibility study of an interventional treatment for erectile dysfunction (ED) that uses a specially-designed drug-eluting stent system.

14 Oct 2009

Underwriters exercise their over-allotment option in purchasing additional Stereotaxis' shares

Stereotaxis, Inc. announced today that the underwriters for the recently announced public offering of Stereotaxis common stock have exercised in full their over-allotment option to purchase an additional 975,000 shares of the Company's common stock. The 7,475,000 shares of Stereotaxis common stock in the offering, including the 975,000 shares subject to the over-allotment option, are being sold at a price to the public of $4.00 per share.

12 Oct 2009

Stereotaxis to offer 6,500,000 shares to the public at $4.00 per share

Stereotaxis, Inc. announced today that it had priced the public offering of 6,500,000 shares of its common at a price to the public of $4.00 per share. Stereotaxis has granted the underwriters of the offering an option to purchase up to an additional 975,000 shares of common stock to cover over-allotments, if any. All of the shares in the offering are being offered by Stereotaxis. Stereotaxis expects the offering to close on October 15, 2009.

9 Oct 2009

Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Statins may have negative effects on some cardiac patients, says study

John Simpson named the 2009 Distinguished Alumnus for his invention

Celsius RMT ThermoCool catheter of Stereotaxis receives CE Mark for distribution in the European market

CCS updates the Canadian guidelines for the management and treatment of dyslipidemia

Treatment of angina patients with ivabradine reduces risk of cardiovascular death

NovaDel and Mist Acquisition enter into licensing agreement to manufacture and commercialize NitroMist

Cappella introduces new Sideguard stent; expands commercial operations

Exercise and lifestyle changes are key to improve heart health

Obese patients less likely to achieve cholesterol and blood pressure control

CHMP grants positive opinion to extend the use of Angiox to patients undergoing PCI

Learn to recognise stroke symptoms and take action: World Stroke Organization

King Pharmaceuticals receives FDA complete response letter for CorVue NDA

Three deaths in Detroit Marathon highlight the importance of greater public awareness about SDC

Boehringer Ingelheim Pharmaceuticals receives NDA approval from FDA for its Micardis Tablets 80 mg

Coronary angiography does not affect kidney functioning in CKD patients, reveals study

Research to investigate and improve patient adherence to prescription drug therapies

Abbott announces financial results for the third quarter ended Sept. 30, 2009

Medtronic commences study of the Zotarolimus-Eluting Peripheral Stent System for treating erectile dysfunction

Underwriters exercise their over-allotment option in purchasing additional Stereotaxis' shares

Stereotaxis to offer 6,500,000 shares to the public at $4.00 per share

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in